$MNKD

Binder Steven B. sold $159K of MNKD

Binder Steven B. sold 39,051 shares of MANNKIND CORP (MNKD) at $4.06 ($0.16M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binder Steven B.
Published Aug 11, 2026, 12:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
high confidence
Mentioned
$MNKD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

The disclosed fact is the sale size, price, and post-transaction holdings, but it does not include any new company performance, guidance, or regulatory development.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates limit trading edge.

03

What to watch

The article does not disclose whether other insiders sold, whether the plan size is typical, or any concurrent company-specific catalysts.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-10, covering a sale dated 2026-08-07.

Background

The article reports an SEC Form 4 insider transaction for MannKind Corp, listing the insider role as director and noting a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$MNKDNeutralHigh confidence
Context

MNKD director Steven B. Binder sold 39,051 shares in an open-market transaction at $4.0600 on 2026-08-07 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, regulatory, or financial datapoint.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales under 10b5-1 can be driven by diversification or liquidity needs rather than bearish expectations, so the market may overreact.

Key entities

  • MannKind Corp

    US-listed company (MNKD) whose director executed an open-market sale under a 10b5-1 plan.

  • Binder Steven B.

    Director who sold 39,051 shares at $4.0600/share on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNKDMedAI 8/10

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth

MannKind (MNKD) advances inhaled IPF drug to global Phase 2, with potential human testing by year-end. CEO Castagna highlights FUROSCIX's strong adoption, shifting sales focus to nephrology. Company reports sufficient cash for growth, aiming for profitability next year. Vicore Pharma's Phase 2b study for IPF treatment expected to report results in summer 2025.

$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.